Search results
17 cze 2022 · The Governing Board of the European Association for the Study of the Liver (EASL) selected a panel of experts to prepare these Clinical Practice Guideline (CPGs) with the purpose of providing the best available evidence on diagnosis and management of hepatic encephalopathy (HE).
- EASL Clinical Practice Guidelines on Sclerosing Cholangitis
Management of primary or secondary sclerosing cholangitis is...
- Volume 77, ISSUE 3
Hepatic and Biliary Cancer; Uncoupling immune trajectories...
- Thematic Miniseries on HCV Cure
The Editors of Journal of Hepatology are pleased to...
- Thematic Miniseries on NAFLD-derived HCC
EASL Congress 2024; Expert Opinion Series; Impact and...
- Thematic Miniseries on Cholangiocarcinoma
BCLC strategy for prognosis prediction and treatment...
- Editorial Board
If the address matches a valid account an email will be sent...
- Current Issue
Hepatic and Biliary Cancer; Glutaryl-CoA dehydrogenase...
- Past Issues
If the address matches a valid account an email will be sent...
- EASL Clinical Practice Guidelines on Sclerosing Cholangitis
We address 5 clinical scenarios that cover most of the diagnostic and therapeutic emergencies in children: infants with liver disease; acute liver failure; management of bleeding varices; liver-based metabolic disorders; and liver tumours and trauma.
Prognosis of these patients is poor; unless there is access to liver transplantation, 1-year survival generally does not exceed 40% 6, 7. Also, minimal HE (mHE) is associated with a significant impact on quality of life and an increased risk of development of overt HE, hospital admission, and death.
6 kwi 2018 · Hepatic encephalopathy is a marker of poor survival 9, 77 and is related to poor QoL. However, its role in ranking patients for liver transplantation priority is difficult, since it is not considered in the model for end-stage liver disease (MELD) score.
2 mar 2020 · There are several risk factors for poor prognosis associated in HE, and these variables in prior publications have included male gender, older age, higher bilirubin, worse renal function, and reduced prothrombin activity.
Prognosis varies and depends on the cause of the hepatic injury, age, and stage of encephalopathy. Survival without LT is highest in the APAP group (94%), whereas children with non-APAP drug-induced ALF (41%), metabolic disease (44%), or indeterminate ALF (43%) fare less well.
Survival Rate. The presence of hepatic encephalopathy is often associated with worse clinical outcomes and increased mortality. Even subclinical hepatic encephalopathy has clinical impacts on daily life and has been linked to increased falls, motor vehicle accidents, and hospitalizations. The presence and degree o …
